🕵️ Actuate Therapeutics, Inc. ($ACTU)
SEC insider & ownership activity, last 12 months · CIK 1652935 · every row links its SEC filing
Over the last 12 months insiders sold $1.6M with no open-market buying against it. Todd S. Thomson sold $1.6M in discretionary trades (Jan). Aaron G.l. Fletcher trimmed 51.3% → 49.8%; BIOS Advisors GP, LLC trimmed 52.4% → 49.5%. One red-flag 8-K in the window: Delisting notice (3.01), Jul 15, 2026.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 1 seller, $1.6M (1 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Todd S. Thomson | 0 | – | 1 | $1.6M | Jan 5, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Aaron G.l. Fletcher | 49.8% | 13D | Jun 27, 2025 | filing ↗ | |
| BIOS Advisors GP, LLC | 49.5% | 13D | Jun 27, 2025 | filing ↗ | |
| BIOS Capital Management, LP | 49.5% | 13D | Jun 27, 2025 | filing ↗ | |
| Leslie W. Kreis | 42.6% | 13D | Jun 27, 2025 | filing ↗ | |
| CAVU Management, LP | 42.2% | 13D | Jun 27, 2025 | filing ↗ | |
| CAVU Advisors, LLC | 42.2% | 13D | Jun 27, 2025 | filing ↗ | |
| BIOS Equity Partners III, LP | 29.2% | 13D | Jun 27, 2025 | filing ↗ | |
| BIOS Fund III QP, LP | 12.3% | 13D | Jun 27, 2025 | filing ↗ | |
| BIOS Actuate Co-Invest II, LP | 10.2% | 13D | Jun 27, 2025 | filing ↗ | |
| BIOS Equity Partners II, LP | 8.5% | 13D | Jun 27, 2025 | filing ↗ | |
| VOSS Capital, LP | 7.7% | 13G | Apr 22, 2026 | filing ↗ | |
| Travis W. Cocke | 7.7% | 13G | Apr 22, 2026 | filing ↗ | |
| BIOS Equity COF, LP | 7.4% | 13D | Jun 27, 2025 | filing ↗ | |
| BIOS Clinical Opportunity Fund, LP | 6.2% | 13D | Jun 27, 2025 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Kairos Venture Partners II, L.P. | $2.1M | Dec 11, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Delisting notice (3.01) | Jul 15, 2026 | filing ↗ |
| Shareholder vote (5.07) | May 21, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 11, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 1, 2026 | filing ↗ |
| Other events (8.01) | May 1, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 1, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 12, 2026 | filing ↗ |
| Material agreement (1.01) | Nov 28, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 28, 2025 | filing ↗ |
| Other events (8.01) | Nov 21, 2025 | filing ↗ |
| Material agreement (1.01) | Sep 10, 2025 | filing ↗ |
| Other events (8.01) | Sep 10, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 10, 2025 | filing ↗ |